This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.
The NIHR is the nation's largest funder of health and care research and provides the people, facilities and technology that enable research to thrive. We work in partnership with the NHS, universities, local government, other research funders (including industry and charities), patients and the public to improve the health and wealth of the nation.
A new gene therapy that has been trialled at the NIHR Imperial Clinical Research Facility could be the first step towards a cure for haemophilia.
People with haemophilia A, the most common type of haemophilia, have a genetic defect that means they do not produce a clotting factor called exogenous factor VIII. In this trial a new therapy that replaces the faulty genes to increase levels of factor VIII was tested in people with severe haemophilia A.
Six of the seven people who received a high dose of the new therapy experienced an increase in factor VIII to normal levels and fewer bleeding events, an effect that was still present a year after the therapy dose.
Currently in the UK women can give blood every 12 weeks and men every 16 weeks. A study jointly funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics and NHS Blood and Transplant has found that giving blood more frequently – up to every 8 weeks for men and every 12 weeks for women – has no major side effects and could help to increase blood stocks, according to recent research.
The results showed that over a two-year period, allowing donors to give blood more frequently boosted the supply of blood to the NHS without having a major impact on their health. The team also found that donors with higher initial stores of iron were able to give more blood, suggesting that better screening methods should be sought to detect low haemoglobin in potential donors.
You can find out more about haematology studies in your areas through the Be Part of Research website.
The NIHR provides researchers with the practical support they need to make clinical studies happen in the NHS. We provide world-class health service infrastructure - research support staff such as clinical research nurses, and research support services such as pharmacy, pathology and radiology - to support organisations seeking to conduct clinical research in the NHS in England. Some of this research is funded by the NIHR, but most of it is funded by NHS non-commercial partners and industry. We also support the set up and delivery of clinical research in the NHS through our Study Support Service and our Research Design Service helps researchers develop proposals to secure funding from our research programmes.
The Haematology specialty is one of over 30 specialties which bring together communities of clinical practice to provide national networks of research expertise. Our membership is made up of research-interested clinicians and practitioners at both national and local levels. Our job is to ensure that haematology studies receive the right support to ensure they are delivered successfully in the NHS.
We oversee research that deals with blood disorders. By this we mean conditions and diseases that affect how the blood and its components work. Haemophilia is one example (an inherited condition that affects the blood’s ability to clot and stop bleeding). Sickle-cell disease is another example (a genetic defect which affects the structure and shape of the blood cells so that it can’t carry oxygen as well as normal cells). Other examples include thrombotic disorders (where the blood clots too much), and anaemia.
We support and promote research in the following areas:
We currently support studies (in both adults and children) investigating:
Blood disorders can have an impact on other parts of the body. Where our research portfolio overlaps with other specialty areas we work closely with our colleagues from across the Network to deliver high quality haematology research
The Clinical Research Network is made up of 15 localities. Each one has at least one nominated local lead for haematology research. These clinicians lead research groups to promote and support haematology research within the NHS Trusts in their area.
At a national level the local leads come together to manage the national haematology research portfolio overall. This involves regularly reviewing the progress of studies, identifying barriers to recruitment, and coming up with solutions and strategies to help overcome those barriers.
HaemSTAR is a UK-wide network of passionate Clinical Haematology registrars supported by the NIHR. The primary aim of HaemSTAR is to promote clinical research into Non-Malignant Haematology.
We aim to do this by:
If you are interested in becoming a HaemSTAR lead or participating as a co-investigator, please contact the national HaemSTAR lead Pip Nicolson on email@example.com.
For more information, visit the HaemSTAR website.
Read more about NIHR haematology in our specialty profile.
The NIHR Haematology specialty group works closely with these organisations in integrating clinical research into NHS clinical service provision, and in driving priority setting that encourages research that will have the greatest impact on patients.
We collaborate with the National Haemophilia Database which maintains a record of patients with bleeding disorders within the UK. This enables us to advise on the incidence of bleeding disorders within the country as well as the location of patients around the country. Such information is anonymised, but can aid in the feasibility assessment of new commercial studies investigating novel therapies in this patient group. We are happy to informally advise our commercial partners about aspects of study design within the UK, particularly regarding patient numbers and the likely location of patients within the UK.
The NIHR partners with NHS Blood and Transplant (NHSBT) on four NIHR Blood and Transplant Research Units (BTRUs).
The BTRUs are research partnerships between universities and NHSBT for research to improve the supply of blood, blood products, stem cells and tissues, and organs for transplantation.
The NIHR provides the support and facilities the NHS needs for first-class research by funding a range of infrastructure.
NIHR Biomedical Research Centres (BRCs), partnerships between England’s leading NHS organisations and universities, conduct translational research to transform scientific breakthroughs into life-saving treatments for patients with haematological conditions. The following BRCs undertake haematology research:
NIHR Medtech and In vitro diagnostics Co-operatives (MICs) build expertise and capacity in the NHS to develop new medical technologies and provide evidence on commercially-supplied in vitro diagnostic tests. The following MIC undertakes research in haematology:
NIHR Blood and Transplant Research Units (BTRUs) are research partnerships between universities and NHS Blood & Transplant (NHSBT). The following BTRUs undertake haematology research:
All of the NIHR facilities and centres are opening to working with the public, charities, industry and other partners. If you are interested in collaborating with the NIHR please contact the NIHR Office for Clinical Research infrastructure: firstname.lastname@example.org
Our experts in the NIHR Clinical Research Network (National Specialty Leads) can give advice on delivering your haematology study in the NHS.
The National Specialty Leads provide leadership on clinical studies in conditions, and act as a key clinical ambassador for these conditions within the specialty.
Dr Dan Hart is the NIHR Clinical Research Network National Specialty Lead for Haematology. He is the Senior Lecturer in Haematology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London, and Honorary Consultant Haematologist at The Royal London Hospital, Barts Health NHS Trust.
He specialises in haemostasis and inherited bleeding disorders with a research interest in the immunobiology and genomic determinants of allo- and autoantibody formation. He is part of a clinical department at Barts Health NHS Trust with colleagues active in a breadth of non-malignant haematology clinical trials, both investigator-initiated and commercially sponsored, from registry hosting (ITP and marrow failure syndromes) to complex, commercial interventional trials (e.g. gene therapy in haemophilia).
Dan has been actively involved locally in NIHR study infrastructure and delivery since it's inception. As CRN North Thames local speciality lead, he has always participated actively at regional and national speciality meetings. Recently, co-deputising for his predecessor, Prof Toh, has given him further insight into NIHR priorities and future strategy. He recognises the importance and challenges of managing a research study portfolio across multiple different sites within a region as well as inter-regional differences in delivery. This is particularly important for a relatively small speciality within the NIHR structure, advocating actively locally and now nationally on behalf of the many very successful haematology investigators across the country.